BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24604590)

  • 1. ¹⁸F-FLT    and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors.
    Wardak M; Schiepers C; Cloughesy TF; Dahlbom M; Phelps ME; Huang SC
    Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1199-209. PubMed ID: 24604590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma.
    Wardak M; Schiepers C; Dahlbom M; Cloughesy T; Chen W; Satyamurthy N; Czernin J; Phelps ME; Huang SC
    Clin Cancer Res; 2011 Oct; 17(20):6553-62. PubMed ID: 21868765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy.
    Schwarzenberg J; Czernin J; Cloughesy TF; Ellingson BM; Pope WB; Grogan T; Elashoff D; Geist C; Silverman DH; Phelps ME; Chen W
    Clin Cancer Res; 2014 Jul; 20(13):3550-9. PubMed ID: 24687922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.
    Harris RJ; Cloughesy TF; Pope WB; Nghiemphu PL; Lai A; Zaw T; Czernin J; Phelps ME; Chen W; Ellingson BM
    Neuro Oncol; 2012 Aug; 14(8):1079-89. PubMed ID: 22711609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
    Chen W; Delaloye S; Silverman DH; Geist C; Czernin J; Sayre J; Satyamurthy N; Pope W; Lai A; Phelps ME; Cloughesy T
    J Clin Oncol; 2007 Oct; 25(30):4714-21. PubMed ID: 17947718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
    Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
    Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
    J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.
    Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH
    Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma.
    Schiepers C; Dahlbom M; Chen W; Cloughesy T; Czernin J; Phelps ME; Huang SC
    J Nucl Med; 2010 May; 51(5):720-7. PubMed ID: 20395318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDOPA kinetics in brain tumors.
    Schiepers C; Chen W; Cloughesy T; Dahlbom M; Huang SC
    J Nucl Med; 2007 Oct; 48(10):1651-61. PubMed ID: 17873130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.
    Bradbury MS; Hambardzumyan D; Zanzonico PB; Schwartz J; Cai S; Burnazi EM; Longo V; Larson SM; Holland EC
    J Nucl Med; 2008 Mar; 49(3):422-9. PubMed ID: 18287265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab.
    Schwarzenberg J; Czernin J; Cloughesy TF; Ellingson BM; Pope WB; Geist C; Dahlbom M; Silverman DH; Satyamurthy N; Phelps ME; Chen W
    J Nucl Med; 2012 Jan; 53(1):29-36. PubMed ID: 22159180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rate of change in maximum
    Oughourlian TC; Yao J; Schlossman J; Raymond C; Ji M; Tatekawa H; Salamon N; Pope WB; Czernin J; Nghiemphu PL; Lai A; Cloughesy TF; Ellingson BM
    J Neurooncol; 2020 Mar; 147(1):135-145. PubMed ID: 31981013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas.
    Tripathi M; Sharma R; D'Souza M; Jaimini A; Panwar P; Varshney R; Datta A; Kumar N; Garg G; Singh D; Grover RK; Mishra AK; Mondal A
    Clin Nucl Med; 2009 Dec; 34(12):878-83. PubMed ID: 20139821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
    Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
    J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.
    Heinzel A; Müller D; Langen KJ; Blaum M; Verburg FA; Mottaghy FM; Galldiks N
    J Nucl Med; 2013 Aug; 54(8):1217-22. PubMed ID: 23785172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
    Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
    J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of 3'-deoxy-3'-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas.
    Zhao F; Cui Y; Li M; Fu Z; Chen Z; Kong L; Yang G; Yu J
    Nucl Med Biol; 2014 Sep; 41(8):710-5. PubMed ID: 24929963
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Patel CB; Fazzari E; Chakhoyan A; Yao J; Raymond C; Nguyen H; Manoukian J; Nguyen N; Pope W; Cloughesy TF; Nghiemphu PL; Czernin J; Lai A; Ellingson BM
    J Neurooncol; 2018 Sep; 139(2):399-409. PubMed ID: 29679199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.